For more information visit us at Forward-Looking Statements The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies and products. (“ProPhase Diagnostics”) to offer COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. The Company is also developing ProPhase Diagnostics, Inc. This includes the development and marketing of dietary supplements under the TK Supplements ® brand. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements.
Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
Copies of the final prospectus supplement (when available) and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., Prospectus Department, 17 State Street, 22nd Floor, New York, New York 10004, telephone at (877) 436-3673 or e-mail at and Dawson James Securities, 101 N Federal Highway Suite 600 Boca Raton, Florida, 33432, Attention: Prospectus Department or by telephone at 1(866) 928-0928 or email at press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at and on ProPhase’s website. Securities and Exchange Commission (the “SEC”). The offering is being made pursuant to an effective shelf registration statement that has been filed with the U.S.
is acting as co-manager for the offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the Offering. ProPhase intends to use the net proceeds from the offering for working capital and other general corporate purposes. The offering is expected to close on January 21, 2021, subject to the satisfaction of customary closing conditions. All of the shares are being offered by ProPhase. In addition, ProPhase has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares to cover over-allotments, if any. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the pricing of an underwritten public offering of 3,000,000 shares of common stock at an offering price of $12.50 per share, for gross proceeds of $37,500,000. 18, 2021 (GLOBE NEWSWIRE) - ProPhase Labs, Inc.
0 kommentar(er)
